Imprimis Pharmaceuticals

NSAID after Dropless approach shown to lower CMEThere was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin—known as the Dropless approach—in addition to an NSAID after cataract surgery.
IV-free sedation may help anxious cataract patientsCataract surgery with or without intravenous sedation can be a factor in the clinical experience. Moving to sublingual sedation may be the next step in safety and comfort for a demanding patient demographic.
Intracanalicular drug depot may fill unmet need for better topical therapyA sustained-release dexamethasone intracanalicular depot may be able to treat post-cataract surgery inflammation without causing spikes in IOP. The product’s one-time administration may also improve compliance and convenience.
Scientific evidence mounting for superior outcomes with dropless cataract surgeryKevin M. Barber, MD, explains how a dropless cataract surgery approach helps to alleviates anxiety, cost burdens, and adherence issues associated with traditional drop therapy.
The effect of drug pricing on cataract surgeryIn a recent wave of drug price increases that can only be explained by pharmaceutical manufacturers’ desire for profit maximization and which doctors and patients may call price gouging, the drug price war has been brought to the doorsteps of many eyecare providers. As optometrists are increasing their practice of medical optometry, patients are now calling their doctors about prior authorizations and unaffordable drug copays.
Express Scripts offers $1 alternative to $750 pillMonths after a manufacturer drew widespread criticism from consumer groups and politicians for raising the price of pyrimethamine (Daraprim) by more than 5000%, Express Scripts, the nation’s largest PBM, has announced it will make the drug available for about $1 per pill.
Express Scripts to offer low-cost option to DaraprimExpress Scripts is partnering with Imprimis Pharmaceuticals to provide access to a low-cost alternative to Daraprim (pyrimethamine). Here's why.
Drug therapies improving refractive outcomesLines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds—phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)—are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.
Intraocular medications gaining traction in cataract proceduresAlthough no new drug therapies entered cataract surgeons’ armamentarium in 2015, interest continues to grow in approaches for intraocular administration.
Dropless cataract surgery yields postoperative prophylaxis for patients, practicesDropless cataract surgery—a combination of anti-infective and anti-inflammatory drugs injected transzonularly or through the pars plana for deposit into the vitreous—reduces the need for topical postoperative drops.